← Back to Search

Methylthioadenosine Phosphorylase (MTAP) Deletion Inhibitor

AG-270 for Lymphoma

Phase 1

Waitlist Available

Research Sponsored by Institut de Recherches Internationales Servier

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 30 weeks, on average

Awards & highlights

Study Summary

This trial will study a new cancer drug in people with advanced solid tumors or lymphoma.

Eligible Conditions

Solid Tumors
Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 30 weeks, on average

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 30 weeks, on average

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 weeks, on average for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of Participants with DLTs Associated with AG-270 Administration During the First Cycle (First 28 Days) of Treatment

Percentage of Participants with DLTs Associated with the Combination of AG-270 and Docetaxel Administration During the First Cycle (First 28 Days) of Treatment

Percentage of Participants with DLTs Associated with the Combination of AG-270, nab-paclitaxel, and Gemcitabine Administration During the First Cycle (First 28 Days) of Treatment

Secondary outcome measures

AUC from 0 to Infinity (AUC0-∞) of AG-270

AUC over One Dosing Interval at Steady State (AUCtau,ss) of AG-270

Apparent Clearance (CL/F) of AG-270

+14 more

Trial Design

3Treatment groups

Experimental Treatment

Group I: AG-270/nab-paclitaxel/gemcitabineExperimental Treatment3 Interventions

AG-270 will be administered daily, starting 1 week prior to nab-paclitaxel and gemcitabine infusion. Starting on Cycle 1 Day 1, nab-paclitaxel and gemcitabine IV will be administered on Days 1,8, and 15 during each 28-day cycle. Treatment with AG-270, nab-paclitaxel, and gemcitabine will continue until disease progression or unacceptable toxicity.

Group II: AG-270/docetaxelExperimental Treatment2 Interventions

AG-270 will be administered daily, starting 1 week prior to docetaxel infusion. Starting on Cycle 1 Day 1, docetaxel (by intravenous infusion [IV]) will be administered once during each 21-day cycle. Treatment with AG-270 and docetaxel will continue until disease progression or unacceptable toxicity.

Group III: AG-270Experimental Treatment1 Intervention

AG-270 will be administered on Days 1 to 28 of each 28-day cycle. Treatment will continue until disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

gemcitabine

2013

Completed Phase 3

~3530

nab-paclitaxel

2008

Completed Phase 4

~1330

docetaxel

2015

Completed Phase 3

~7230

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Institut de Recherches Internationales ServierLead Sponsor

86 Previous Clinical Trials

67,013 Total Patients Enrolled

2 Trials studying Lymphoma

125 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients still being accepted for participation in this research endeavor?

"This trial is no longer accepting participants as it was last edited on July 29th, 2022. If you are looking for alternative trials, there are currently 2166 clinical studies enrolling patients with lymphoma and 1344 registries recruiting individuals to participate in AG-270 research."

Answered by AI

Has the Food & Drug Administration sanctioned AG-270 for public use?

"Our assessment of AG-270 safety is a 1, as this initial phase of the trial has not yet gathered sufficient evidence to support its efficacy and security."

Answered by AI

How extensively is this clinical inquiry being conducted in Canada?

"Currently, 9 clinics are running this research trial. Some of the sites can be found in Nashville, New york and New Haven along with 6 other locations. To reduce travel requirements for participants it is essential to pick a clinic close by."

Answered by AI

What have medical professionals prescribed AG-270 to treat?

"AG-270 is primarily prescribed for individuals with the BRCA1 gene mutation. It has also been successfully administered to patients suffering from refractory testicular germ cell cancer, advanced directives, and pancreatic adenocarcinoma locally advanced."

Answered by AI

How many participants is this trial accepting?

"This trial has already ended its open recruitment period, which began on the 4th of March 2018 and concluded on the 29th July 2022. However, if you are still searching for clinical trials involving lymphoma there are 2166 studies that currently have openings and 1344 specifically examining AG-270."

Answered by AI

Have other researchers delved into AG-270?

"AG-270 was first examined in 1997 by researchers at City of Hope Comprehensive Cancer Center. Since this time, a total of 2516 trials have been concluded. 1344 more are presently underway, mainly based out of Nashville, Tennessee."

Answered by AI

Recent research and studies

mtapJournal

Discovery of AG-270, a First-in-class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>mtap</i> Deletion

Konteatis, Zenon, Jeremy Travins, Stefan Gross, Katya Marjon, Amelia Barnett, Everton Mandley, Brandon Nicolay, et al.. 2021. “Discovery of AG-270, a First-in-class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous mtap Deletion”. Journal of Medicinal Chemistry. American Chemical Society (ACS). doi:10.1021/acs.jmedchem.0c01895.

clinicaltrials.govStudy

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

2018. "Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03435250.